Our findings establish CD109 as an essential regulator of IL-6-mediated oncogenic activity promoting cancer cell stemness and antioxidant state in SCC cells, providing mechanistic insights into IL-6-mediated cell survival and resistance to therapy in SCC. Here, IL6 is linked to cancer.